231 related articles for article (PubMed ID: 17495874)
1. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
[TBL] [Abstract][Full Text] [Related]
2. Role of itraconazole metabolites in CYP3A4 inhibition.
Isoherranen N; Kunze KL; Allen KE; Nelson WL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1121-31. PubMed ID: 15242978
[TBL] [Abstract][Full Text] [Related]
3. Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Kunze KL; Nelson WL; Kharasch ED; Thummel KE; Isoherranen N
Drug Metab Dispos; 2006 Apr; 34(4):583-90. PubMed ID: 16415110
[TBL] [Abstract][Full Text] [Related]
4. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
Quinney SK; Galinsky RE; Jiyamapa-Serna VA; Chen Y; Hamman MA; Hall SD; Kimura RE
Drug Metab Dispos; 2008 Jun; 36(6):1097-101. PubMed ID: 18339815
[TBL] [Abstract][Full Text] [Related]
6. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
Templeton I; Peng CC; Thummel KE; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2010 Oct; 88(4):499-505. PubMed ID: 20739919
[TBL] [Abstract][Full Text] [Related]
7. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
8. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole.
Mino Y; Naito T; Watanabe T; Yamada T; Yagi T; Yamada H; Kawakami J
Clin Chim Acta; 2013 Jan; 415():128-32. PubMed ID: 23089073
[TBL] [Abstract][Full Text] [Related]
9. In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.
Krasulova K; Dvorak Z; Anzenbacher P
Xenobiotica; 2019 Jan; 49(1):36-42. PubMed ID: 29320899
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry.
Liang X; Van Parys M; Ding X; Zeng N; Bi L; Dorshort D; McKnight J; Milanowski D; Mao J; Chen Y; Ware JA; Dean B; Hop CE; Deng Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():111-9. PubMed ID: 27038403
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
15. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
Peng CC; Shi W; Lutz JD; Kunze KL; Liu JO; Nelson WL; Isoherranen N
Drug Metab Dispos; 2012 Mar; 40(3):426-35. PubMed ID: 22106171
[TBL] [Abstract][Full Text] [Related]
16. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
17. Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes.
Gubbins PO; Melchert RB; McConnell SA; Franks AM; Penzak SR; Gurley BJ
Pharmacology; 2003 Apr; 67(4):195-201. PubMed ID: 12595750
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including
Imoto Y; Mino Y; Naito T; Ono T; Kawakami J
J Pharm Health Care Sci; 2020; 6():11. PubMed ID: 32391164
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
20. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.
Ni L; Yu X; Yu Q; Chen X; Jia L
Drug Metab Lett; 2008 Aug; 2(3):163-8. PubMed ID: 19356088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
